Decoy Therapeutics Inc.

Market Cap

$4M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$6.30-$1.52 (-19.48%)

Jun 22, 2026

52W High $216.0052W Low $4.41

Company Details

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform tha...

Leadership

Frederick E. Pierce II

CEO & Director

Mark J. Rosenblum CPA

Executive VP of Finance & CFO

Barbara Hibner Ph.D.

Chief Scientific Officer

Peter K. Marschel M.B.A., M.S.

Chief Business Officer

Nadeem Q. Mirza M.D., M.P.H.

Senior Vice President of Clinical Development

IPO Date

Jan 7, 2026

Website

decoytx.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$13M

EPS (Diluted)

Free Cash Flow

-$7M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee